China speed: Data, deals, first-in-class assets — a BioCentury podcast

Ahead of China Healthcare Summit this October, industry leaders discuss implications of seemingly insatiable Western appetite for China innovation

Dealmaking between Western and Chinese biopharmas has been one of the year’s bright spots, as a maturing biotech landscape in China converges with Western demand for innovative assets, driving record deal flow. At the same time, the Hong Kong stock exchange has emerged as the hottest market for biotech IPOs, at a time when the NASDAQ window remains shut.

These themes — China’s burgeoning biotech innovation, dealmaking strategies, and green shoots in the Hong Kong capital markets — will be in the spotlight at the 12th BioCentury-BayHelix China Healthcare Summit this fall. McKinsey & Company is returning as insights partner for the conference, which runs Oct. 22-24 in Shanghai.

On this special edition of the BioCentury This Week podcast, a trio of biopharma leaders join BioCentury’s analysts to discuss the landscape: Franck Le Deu, a senior partner at McKinsey who co-leads the firm’s Asia healthcare practice; Ji Li, a former top BD executive at biopharmas such as Merck & Co. Inc. (NYSE:MRK) and BeOne Medicines Ltd. (NASDAQ:BGNE; HKEX:6160; Shanghai:688235; formerly BeiGene) who is now a consultant on cross-border deals; and Mike Patten, chief strategy officer at HBM Holdings Ltd. (HKEX:02142) (Harbour Biomed).

BioCentury, BayHelix and Insights Partner McKinsey & Company invite you to visit Shanghai for the 12th China Healthcare Summit at the St. Regis Shanghai Jingan. For more information, click here; to apply to join the 2025 Class of Presenting Companies click here.